0000899243-21-013801.txt : 20210329 0000899243-21-013801.hdr.sgml : 20210329 20210329162019 ACCESSION NUMBER: 0000899243-21-013801 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210325 FILED AS OF DATE: 20210329 DATE AS OF CHANGE: 20210329 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Krieg Arthur M CENTRAL INDEX KEY: 0001335659 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 21781920 MAIL ADDRESS: STREET 1: C/O CHECKMATE PHARMACEUTICALS, INC. STREET 2: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001651431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364813934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 978-503-2124 MAIL ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-25 0 0001651431 Checkmate Pharmaceuticals, Inc. CMPI 0001335659 Krieg Arthur M C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 0 1 0 0 Chief Scientific Officer Common Stock 2021-03-25 4 P 0 10036 12.35 A 743227 D Common Stock 2021-03-26 4 P 0 3484 12.15 A 746711 D Common Stock 68457 I See Footnote Common Stock 68457 I See Footnote Common Stock 68457 I See Footnote The price reported in column 4 is a weighted average price. Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, these shares were purchased in multiple transactions, at prices ranging from $12.11 to $12.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in column 4 is a weighted average price. Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, these shares were purchased in multiple transactions, at prices ranging from $12.00 to $12.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The shares are held by an irrevocable trust for the Reporting Person's child. The Reporting Person serves as trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. /s/ Kleem Chaudhary, attorney-in-fact 2021-03-29